<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Immune thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> is an <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> occasionally associated with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> for which oral <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> constitute the first-line treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Therapy may be complex, particularly in the event of a contraindication to the standard treatment, namely <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, splenectomy or <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We report the case of a patient with systemic <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> associated with immune thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> and multisystem <z:e sem="disease" ids="C0041296" disease_type="Disease or Syndrome" abbrv="tb|tbc">tuberculosis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Because of a contraindication to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, the patient was successfully treated with rituximab (anti-CD20 antibody) </plain></SENT>
<SENT sid="4" pm="."><plain>This medication (Mabthera) is indicated in the treatment of relapsing or refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>CASE REPORT: A 31-year-old North African woman had been treated for 10 years with <z:chebi fb="0" ids="8382">prednisone</z:chebi>, hydroxychloroquine, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> for <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>She presented severe immune thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> (platelet count: 4G/l) 3 months after initiation of <z:chebi fb="0" ids="33231">antitubercular</z:chebi> treatment for multisystem <z:e sem="disease" ids="C0041296" disease_type="Disease or Syndrome" abbrv="tb|tbc">tuberculosis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The patient was unsuccessfully treated at the outset with 3 infusions of intravenous immunoglobulin </plain></SENT>
<SENT sid="8" pm="."><plain>Since <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> remained under 5 G/l, she was given rituximab 375 mg/m2/week for 4 weeks </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> and native anti-DNA antibody levels decreased after the third infusion (D16) </plain></SENT>
<SENT sid="10" pm="."><plain>No side effects of treatment were observed </plain></SENT>
<SENT sid="11" pm="."><plain>The patient did not experience any relapse during the 29 months following the final infusion </plain></SENT>
<SENT sid="12" pm="."><plain>DISCUSSION: In the present case, rituximab was used because of multisystem <z:e sem="disease" ids="C0041296" disease_type="Disease or Syndrome" abbrv="tb|tbc">tuberculosis</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Rituximab appears to constitute a safe and effective treatment for refractory immune thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> associated with SLE in patients having a contraindication to or refractory to conventional therapy </plain></SENT>
</text></document>